Momentum Bioscience is focused on developing rapid tests for bloodstream infection in patients suspected of sepsis. SepsiSTAT® is our direct-from-blood, rapid screening technology, providing actionable results for suspected sepsis patients. SepsiSTAT® contains our three proprietary capabilities: 1. Sensitive and universal microbial capture 2. Universal detection of viable microorganisms 3. Organism profiling Only by using Momentum’s proprietary universal pathogen capture, detection & identification capabilities can all patients suspected of sepsis expect actionable results for bloodstream infection in <3 hours. Not days. This will have a significant impact on patient management, the management of antibiotics and help mitigate the problem of increasing antimicrobial resistance. Momentum is seeking partners for joint commercialisation. Momentum was founded in 2008 to develop rapid tests for critically-important clinical specimens within the hospital microbiology laboratory. The Company is backed by its founders, business angels and venture capital. Momentum is headquartered near Cardiff and has a R&D facility near Oxford in the UK.